FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171567692> ?p ?o ?g. }

• W2171567692 endingPage "897" @default.
• W2171567692 startingPage "889" @default.
• W2171567692 abstract "Supplementary immunisation activities with oral poliovirus vaccines (OPVs) are usually separated by 4 week intervals; however, shorter intervals have been used in security-compromised areas and for rapid outbreak responses. We assessed the immunogenicity of monovalent type-1 oral poliovirus vaccine (mOPV1) given at shorter than usual intervals in Karachi, Pakistan.This was a multicentre, randomised, controlled, four-arm, open-label, non-inferiority trial done at five primary health-care centres in low-income communities in and around Karachi, Pakistan. Eligible participants were healthy newborn babies with a birthweight of at least 2·5 kg, for whom informed consent was provided by their parent or guardian, and lived less than 30 km from the study clinic. After receiving a birth dose of trivalent OPV, we enrolled and randomly assigned newborn babies (1:1:1:1) to receive two doses of mOPV1 with an interval of 1 week (mOPV1-1 week), 2 weeks (mOPV1-2 weeks), or 4 weeks (mOPV1-4 weeks) between doses, or two doses of bivalent OPV (bOPV) with an interval of 4 weeks between doses (bOPV-4 weeks). We gave the first study dose of OPV at age 6 weeks. We did the randomisation with a centrally generated, computerised allocation sequence with blocks of 16; participants' families and study physicians could not feasibly be masked to the allocations. Trial participants were excluded from local supplementary immunisation activities during the study period. The primary outcome was non-inferiority (within a 20% margin) between groups in seroconversion to type-1 poliovirus. The primary and safety analyses were done in the per-protocol population of infants who received all three doses of vaccine. This trial is registered with ClinicalTrials.gov, number NCT01586572, and is closed to new participants.Between March 1, 2012, and May 31, 2013, we enrolled 1009 newborn babies, and randomly assigned 829 (82%) to treatment. 554 (67%) of the 829 babies were included in the per-protocol analysis. Proportions of seroconversion to type-1 poliovirus were 107/135 (79%, 95% CI 72·4-86·1) with mOPV1-1 week, 108/135 (80%, 73·2-86·8) with mOPV1-2 weeks, 129/148 (87%, 80·9-92·0) with mOPV1-4 weeks, and 107/136 (79%, 71·8-85·6) with bOPV-4 weeks. Non-inferiority was shown between groups and no significant differences were noted. Ten participants died during the trial. Seven of these deaths occurred during the lead-in period before randomisation (two from diarrhoea, five from unknown causes). Three infants died from sepsis after random assignment. No deaths were attributed to the procedures or vaccines. Additionally, we noted no events of vaccine-associated paralysis.We identified no significant differences in responses to mOPV1 given with shorter intervals between doses than with the standard 4 week intervals. The short-interval strategy could be particularly beneficial when temporary windows of opportunity for safe access can be granted in areas of conflict--eg, during cease-fire periods. In such situations, we recommend shortening the interval between OPV doses to 7 days.World Health Organization." @default.
• W2171567692 created "2016-06-24" @default.
• W2171567692 creator A5006863999 @default.
• W2171567692 creator A5009955994 @default.
• W2171567692 creator A5011516348 @default.
• W2171567692 creator A5013167258 @default.
• W2171567692 creator A5022426711 @default.
• W2171567692 creator A5032828510 @default.
• W2171567692 creator A5036590679 @default.
• W2171567692 creator A5040508836 @default.
• W2171567692 creator A5043041341 @default.
• W2171567692 creator A5044358742 @default.
• W2171567692 creator A5052928718 @default.
• W2171567692 creator A5078019140 @default.
• W2171567692 creator A5085793844 @default.
• W2171567692 date "2015-08-01" @default.
• W2171567692 modified "2023-10-01" @default.
• W2171567692 title "Monovalent type-1 oral poliovirus vaccine given at short intervals in Pakistan: a randomised controlled, four-arm, open-label, non-inferiority trial" @default.
• W2171567692 cites W1568551926 @default.
• W2171567692 cites W1965206227 @default.
• W2171567692 cites W1970173301 @default.
• W2171567692 cites W1973869449 @default.
• W2171567692 cites W2003027106 @default.
• W2171567692 cites W2012113393 @default.
• W2171567692 cites W2012921340 @default.
• W2171567692 cites W2017447934 @default.
• W2171567692 cites W2021391690 @default.
• W2171567692 cites W2031852507 @default.
• W2171567692 cites W2040705304 @default.
• W2171567692 cites W2040799363 @default.
• W2171567692 cites W2069543300 @default.
• W2171567692 cites W2075892057 @default.
• W2171567692 cites W2082002269 @default.
• W2171567692 cites W2097799404 @default.
• W2171567692 cites W2098993743 @default.
• W2171567692 cites W2109715645 @default.
• W2171567692 cites W2125876252 @default.
• W2171567692 cites W2131450822 @default.
• W2171567692 cites W2161723369 @default.
• W2171567692 cites W2307617917 @default.
• W2171567692 cites W2315181287 @default.
• W2171567692 cites W2337824450 @default.
• W2171567692 cites W4246712049 @default.
• W2171567692 cites W4246757520 @default.
• W2171567692 doi "https://doi.org/10.1016/s1473-3099(15)00093-6" @default.
• W2171567692 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4644524" @default.
• W2171567692 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26093979" @default.
• W2171567692 hasPublicationYear "2015" @default.
• W2171567692 type Work @default.
• W2171567692 sameAs 2171567692 @default.
• W2171567692 citedByCount "15" @default.
• W2171567692 countsByYear W21715676922015 @default.
• W2171567692 countsByYear W21715676922016 @default.
• W2171567692 countsByYear W21715676922017 @default.
• W2171567692 countsByYear W21715676922018 @default.
• W2171567692 countsByYear W21715676922019 @default.
• W2171567692 countsByYear W21715676922023 @default.
• W2171567692 crossrefType "journal-article" @default.
• W2171567692 hasAuthorship W2171567692A5006863999 @default.
• W2171567692 hasAuthorship W2171567692A5009955994 @default.
• W2171567692 hasAuthorship W2171567692A5011516348 @default.
• W2171567692 hasAuthorship W2171567692A5013167258 @default.
• W2171567692 hasAuthorship W2171567692A5022426711 @default.
• W2171567692 hasAuthorship W2171567692A5032828510 @default.
• W2171567692 hasAuthorship W2171567692A5036590679 @default.
• W2171567692 hasAuthorship W2171567692A5040508836 @default.
• W2171567692 hasAuthorship W2171567692A5043041341 @default.
• W2171567692 hasAuthorship W2171567692A5044358742 @default.
• W2171567692 hasAuthorship W2171567692A5052928718 @default.
• W2171567692 hasAuthorship W2171567692A5078019140 @default.
• W2171567692 hasAuthorship W2171567692A5085793844 @default.
• W2171567692 hasBestOaLocation W21715676922 @default.
• W2171567692 hasConcept C126322002 @default.
• W2171567692 hasConcept C168563851 @default.
• W2171567692 hasConcept C187212893 @default.
• W2171567692 hasConcept C202953159 @default.
• W2171567692 hasConcept C203014093 @default.
• W2171567692 hasConcept C2522874641 @default.
• W2171567692 hasConcept C2777451964 @default.
• W2171567692 hasConcept C2779631682 @default.
• W2171567692 hasConcept C3013748606 @default.
• W2171567692 hasConcept C44249647 @default.
• W2171567692 hasConcept C512399662 @default.
• W2171567692 hasConcept C71924100 @default.
• W2171567692 hasConceptScore W2171567692C126322002 @default.
• W2171567692 hasConceptScore W2171567692C168563851 @default.
• W2171567692 hasConceptScore W2171567692C187212893 @default.
• W2171567692 hasConceptScore W2171567692C202953159 @default.
• W2171567692 hasConceptScore W2171567692C203014093 @default.
• W2171567692 hasConceptScore W2171567692C2522874641 @default.
• W2171567692 hasConceptScore W2171567692C2777451964 @default.
• W2171567692 hasConceptScore W2171567692C2779631682 @default.
• W2171567692 hasConceptScore W2171567692C3013748606 @default.
• W2171567692 hasConceptScore W2171567692C44249647 @default.
• W2171567692 hasConceptScore W2171567692C512399662 @default.
• W2171567692 hasConceptScore W2171567692C71924100 @default.
• W2171567692 hasIssue "8" @default.
• W2171567692 hasLocation W21715676921 @default.

• next